Effect of long-term treatment with platelet-activating factor on IL-1 and IL-2 production by rat spleen cells.

To study the effect of the in vivo administration of platelet-activating factor (PAF) on cytokine production, alzet minipumps loaded with the mediator or solvent alone were connected to the jugular vein and placed under the skin of Sprague-Dawley rats. Over 7 days the animals received total doses of 0.5, 1, 4.5, 9, or 28 micrograms PAF or the solvent alone. The spleen mononuclear cells isolated from Ficoll gradients and the adherent cell fraction were separated before determination of basal and mitogen-stimulated IL-1 and IL-2 production, respectively. Adherent splenocytes from rats having received 28 micrograms PAF exhibited a decreased capability to produce IL-1, as compared to those from vehicle-treated animals. In contrast, adherent splenocytes from rats having received 9 and 4.5 micrograms PAF yielded higher amounts of released and cell-associated IL-1 activity upon LPS stimulation, as compared to those from solvent-treated animals. The PAF antagonist, BN 52021, given orally (5 mg/kg, twice a day throughout the experiments) inhibited the in vivo effect of 28 micrograms PAF. Statistically significant 144 +/- 43% (p less than 0.001, n = 5) and 73 +/- 33%, (p less than 0.01, n = 3) increases in IL-2 production were observed when whole spleen mononuclear cells from rats administered with 1 and 4.5 micrograms PAF, respectively, were stimulated with Con A. BN 52021 markedly inhibited the in vivo effect of 1 microgram PAF on the IL-2 release. Our study demonstrates that PAF can modulate immune functions in vivo and suggests that the specific PAF antagonist, BN 52021, may be used as an immunomodulatory agent.

• Publication year

  1990

• Venue

  Journal of Immunology

• Publication date

  1990-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.145.3.980PMID 2373865
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of platelet-activating factor (PAF-acether) and its specific receptor antagonist, BN 52021, on interleukin 1 (IL1) release and synthesis by rat spleen adherent monocytes.

  1987cited by this paper
• Inhibition of human lymphocyte proliferation and interleukin 2 production by platelet activating factor (PAF-acether): reversal by a specific antagonist, BN 52021.

  1987cited by this paper
• Role of interleukin 1 in antigen-specific T cell proliferation.

  1984cited by this paper
• Antigen-initiated release of platelet-activating factor (PAF-acether) from mouse bone marrow-derived mast cells sensitized with monoclonal IgE.

  1983cited by this paper
• Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators).

  1979cited by this paper
• [Semi-synthesis and proposed structure of platelet-activating factor (P.A.F.): PAF-acether an alkyl ether analog of lysophosphatidylcholine].

  1979cited by this paper
• Platelet‐activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes

  1979cited by this paper
• Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils.

  1979cited by this paper
• Characterization of lymphocyte-activating factor (LAF) produced by a macrophage cell line, P388D1. II. Biochemical characterization of LAF induced by activated T cells and LPS.

  1978cited by this paper
• T cell growth factor: parameters of production and a quantitative microassay for activity.

  1978cited by this paper
• Cytochemical identification of monocytes and granulocytes.

  1971cited by this paper

• Indoleamine 2,3-dioxygenase and inducible nitric oxide synthase mediate immune tolerance induced by CTLA4Ig and anti-CD154 hematopoietic stem cell transplantation in a sensitized mouse model

  2017influential citation
• Direct action of platelet activating factor (PAF) induces eosinophil accumulation and enhances expression of PAF receptors in conjunctivitis.

  2005cites this paper
• Janus Kinase 2 Activation by the Platelet-Activating Factor Receptor (PAFR): Roles of Tyk2 and PAFR C Terminus1

  2003cites this paper
• A platelet activating factor receptor antagonist prevents the development of chronic arthritis in mice.

  1999cites this paper
• A nnals of the R heumatic D iseases PAF, a potent proinflammatory mediator, looking for its role in the pathogenesis of joint damage

  1998cites this paper
• PAF, a potent proinflammatory mediator, looking for its role in the pathogenesis of joint damage

  1997cites this paper
• Platelet-Activating Factor: Biosynthesis, Biodegradation, Actions

  1997cites this paper
• Comparison of hypotensive response to aggregated IgG or to bacterial LPS in rats

  1997cites this paper
• PLATELET‐ACTIVATING FACTOR (PAF) IN EXPERIMENTAL AND CLINICAL SEPSIS

  1997cites this paper
• Platelet-Activating Factor and Its Antagonists: Scientific Background and Clinical Applications of Ginkgolides

  1997cites this paper
• Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis.

  1996cites this paper
• Role for intracellular platelet‐activating factor in the circulatory failure in a model of Gram‐positive shock

  1995cites this paper
• IL-1 beta and IL-6 stimulate the production of platelet-activating factor (PAF) by cultured rabbit synovial cells.

  1995cites this paper
• PAF and haematopoiesis. IV. Modifications of spleen and thymus PAF contents after a single dose of the chemotherapeutic drug 5-fluorouracil in mice.

  1995cites this paper
• IL‐1β and IL‐6 stimulate the production of platelet‐activating factor (PAF) cultured rabbit synovial cells

  1995cites this paper
• Effect of platelet activating factor (PAF) on the migration of human lymphocytes.

  1995cites this paper
• Platelet-activating factor and the cytokine network in inflammatory processes

  1995cites this paper
• Cytokines and eicosanoids regulate PAF receptor gene expression.

  1995cites this paper
• Platelet-activating factor and human blood monocytes: an overview

  1995cites this paper
• Clinical experience with platelet-activating factor antagonists

  1995cites this paper
• Clinical experience with platelet-activating factor antagonists. Past, present, and near future.

  1994cites this paper
• Cell–Cell Interaction of Macrophages and Vascular Smooth Muscle Cells in the Synthesis of Leukotriene B4

  1994cites this paper
• Platelet-Activating Factor: Pathophysiological Changes and Therapeutic Implications in Sepsis

  1994cites this paper
• Platelet-activating factor antagonists: scientific background and possible clinical applications.

  1994cites this paper
• PAF-cytokine autocatalytic feed-back network in septic shock: involvement in acute renal failure.

  1994cites this paper
• Effects of platelet-activating factor on human T and B cells--an overview.

  1994cites this paper
• 8 – Biological Properties of Platelet-Activating Factor

  1994cites this paper
• Effect of Platelet-activating Factor on in vitro and in vivo Interleukin-6 Production

  1994cites this paper
• Cloning, expression and tissue distribution of rat platelet-activating-factor-receptor cDNA.

  1994cites this paper
• Priming of Monocytes with Interferon‐Gamma Is Associated with Up‐Regulation of Expression of the Receptor for Platelet‐Activating Factor a

  1994cites this paper
• Platelet-activating factor triggers the phosphorylation and activation of MAP-2 kinase and S6 peptide kinase activity in human B cell lines.

  1993cites this paper
• Protection from BB rat diabetes by the platelet-activating factor inhibitor BN50730.

  1993cites this paper
• The Interaction of Interleukin-1 With the Actors of Asthma

  1993cites this paper
• PAF-induced amplification of mediator release in septic shock: prevention or downregulation by PAF antagonists.

  1993cites this paper
• Role of PAF and cytokines in microvascular tissue injury.

  1992cites this paper
• Circulating cytokines: the tip of the iceberg?

  1992cites this paper
• Stimulation of tumour necrosis factor release by cytotoxic analogues of platelet-activating factor.

  1992cites this paper
• Cytokine gene regulation by PGE2, LTB4 and PAF

  1992cites this paper
• Platelet activating factor mediates interleukin-2-induced lung injury in the rat.

  1992cites this paper
• Platelet-activating factor enhances interleukin-6 production by alveolar macrophages.

  1992cites this paper
• Differentiation‐dependent modulation of TNF production by PAF in human HL‐60 myeloid leukemia cells

  1992cites this paper
• PAF, Cytokines and Cell to Cell Interactions in Shock and Sepsis

  1992cites this paper
• Modulation of Cytotoxic Processes by Platelet-Activating Factor

  1992cites this paper
• Modulation of Cytokine Gene Expression by LTB4 and PAF: Transcriptional and Post-Transcriptional Regulation

  1991cites this paper
• Platelet-activating factor (PAF-acether) enhances the concomitant production of tumour necrosis factor-alpha and interleukin-1 by subsets of human monocytes.

  1991cites this paper
• LTB4 and PAF in the cytokine network.

  1991cites this paper
• [Paf-acether and digestive tract].

  1991cites this paper
• Cell-Cell Interactions in the Release of Inflammatory Mediators

  1991cites this paper
• PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

  1991cites this paper
• Cardiopulmonary and intravascular alterations during the sustained infusion of PAF.

  1991cites this paper
• A nnals of the R heumatic D iseases

  year unknowncites this paper